Picture of Seikagaku logo

4548 Seikagaku Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareConservativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+4.5%
3m-6.92%
6m-21.66%
1yr-32.58%
Volume Change (%)
10d/3m-7.49%
Price vs... (%)
52w High-13.65%
50d MA-2.38%
200d MA-4.16%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)22.91
PEG Ratio (f)n/a
EPS Growth (f)-32.29%
Dividend Yield (f)3.51%
Valuation (ttm)IndustryMarket
Price to Book Value0.56
Price to Tang. Book0.59
Price to Free Cashflown/a
Price to Sales1.16
EV to EBITDA7.2

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital1.36%
Return on Equity1.85%
Operating Margin2.9%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue¥m28,38428,64227,73434,85133,45636,10034,5002.09%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-42.27n/an/a-8.84-37.74+9.24-32.29n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Seikagaku EPS forecast chart

Profile Summary

SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
June 2nd, 1947
Public Since
March 23rd, 2004
No. of Shareholders
10,285
No. of Employees
976
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
54,560,374

4548 Share Price Performance

Upcoming Events for 4548

Full Year 2024 Seikagaku Corp Earnings Release

Seikagaku Corp Annual Shareholders Meeting

Q1 2025 Seikagaku Corp Earnings Release

Similar to 4548

Picture of Astellas Pharma logo

Astellas Pharma

jp flag iconTokyo Stock Exchange

Picture of Astena Holdings Co logo

Astena Holdings Co

jp flag iconTokyo Stock Exchange

Picture of CanBas Co logo

CanBas Co

jp flag iconTokyo Stock Exchange

Picture of CellSeed logo

CellSeed

jp flag iconTokyo Stock Exchange

FAQ